Business context and reporting period
The supplied filing is Cerulean Pharma Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2016, filed November 3, 2016. It does not identify Dare Bioscience, Inc. as the registrant; verify the issuer before relying on this summary. Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates (NDCs), with no product-sales revenue.
Financial performance and position
| Metric | Q3 2016 / September 30, 2016 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q3 2015 |
| Research and development expense | $7.1 million for Q3; $24.4 million for nine months | $7.1 million and $18.8 million, respectively, in 2015 |
| General and administrative expense | $2.4 million for Q3; $8.3 million for nine months | $3.0 million and $8.4 million, respectively, in 2015 |
| Net loss | $10.0 million for Q3; $34.4 million for nine months | $10.6 million and $28.9 million, respectively, in 2015 |
| Net loss per share, basic and diluted | $0.36 for Q3; $1.26 for nine months | $0.39 and $1.17, respectively, in 2015 |
| Cash and cash equivalents | $38.1 million | $75.9 million at December 31, 2015 |
| Loan payable | $14.7 million carrying value; approximately $15.1 million outstanding before related accounting adjustments | $20.3 million carrying value at December 31, 2015 |
| Accumulated deficit | $195.7 million | $161.4 million at December 31, 2015 |
For the first nine months, operating cash use was $31.7 million versus $23.7 million in 2015; investing cash use was $0.4 million. Financing used $5.8 million, chiefly for $5.9 million of loan principal payments, compared with $50.5 million of financing cash provided in 2015, largely from an equity offering and borrowings. Cash declined $37.9 million to $38.1 million. No operating margin was meaningful because the company reported no revenue.
Material changes and notable developments
- Nine-month R&D expense rose 30% to $24.4 million, principally from higher CRLX101 manufacturing and development costs; CRLX101 spending increased 29% and CRLX301 spending increased 50% year over year.
- Nine-month net loss increased 19% to $34.4 million. Q3 net loss improved 6% year over year, partly as G&A expense fell 20% following cost reductions.
- In August 2016, Cerulean announced a workforce reduction of approximately 48% to cut costs and refocus CRLX101 development. It recorded about $0.3 million of restructuring charges in Q3, with substantially all expected to be paid by March 31, 2017.
- CRLX101 plus Avastin failed to show a statistically significant difference in median progression-free survival or objective response rate versus standard-of-care therapy in a Phase 2 renal-cell-carcinoma trial. Cerulean surrendered its fast-track designation for that indication and discontinued development there.
Outlook, risks, and contingencies
- Management said September cash, together with October proceeds of $1.0 million from Aspire Capital and a $5.0 million upfront Novartis collaboration payment, was expected to fund planned operations for at least 12 months following the report date. Additional capital is needed for long-term operations; funding availability and terms are uncertain.
- The Aspire agreement permits up to $20.0 million of common-stock purchases over 24 months. Cerulean issued 700,000 commitment shares and sold 800,000 shares for $1.0 million initially; the remaining $19.0 million was subject to agreement terms and limitations, and future sales could dilute shareholders.
- Under the October 2016 Novartis collaboration, Cerulean will create NDC candidates using Novartis-selected drug ingredients; Novartis will lead development and commercialization. Cerulean received $5.0 million upfront and may receive employee-cost funding, milestones, and royalties, but future amounts depend on collaboration progress and commercial outcomes.
- Management expected near-term R&D and G&A expenses to decline following the workforce reduction and collaboration-related reimbursement. This is not a quantified earnings or revenue forecast.
- CRLX101’s ovarian-cancer combination trial with paclitaxel was ongoing; further data were expected in 2017. The filing also cites slower-than-expected enrollment. CRLX301 remained in Phase 1/2a dose-schedule evaluation.
- Key risks include clinical failure or delay, the need for additional financing, possible equity dilution, debt-service and covenant obligations, dependence on third-party manufacturers and clinical contractors, and uncertainty around intellectual-property rights. The Hercules loan matures July 1, 2018, bears a floating rate, and is secured by substantially all assets other than intellectual property; the company also described an IP negative pledge.
- The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It reported no off-balance-sheet arrangements and no material change in contractual obligations outside the ordinary course.
Important facts for investors to verify
- Confirm the issuer: the supplied document is Cerulean Pharma Inc., not Dare Bioscience, Inc.
- Check subsequent cash balances, cash burn, and whether the stated 12-month runway assumption was achieved.
- Review actual use and availability of the Aspire equity facility, including share issuance and dilution.
- Track Novartis collaboration funding, research progress, milestones, and any resulting royalties.
- Assess new clinical data and enrollment progress for CRLX101 and CRLX301, particularly after the failed renal-cancer study.
- Review Hercules loan balances, repayment requirements, covenants, and collateral provisions.